The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is now priced at $3.97 and the shares are 0.05 points up or 1.28% higher compared to its previous closing price of $3.92. The stock had 3.925 million contracts set over the past session. BCRX shares’ daily volume is compared to its average trading volume at 6.865 million shares. However, it has a float of 161 million and although its performance was -4.68% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the BCRX share price recently placing at $3.86 to $4.02. However, some brokerage firms have priced the stock below the average, including one that has called $4.5.
The shorts are climbing into the BioCryst Pharmaceuticals, Inc. stock, with the latest data on short interest released on August 14, 2020, showing that short interest numbers in the BCRX shares have risen. Short interest in the stock represents just 23.6% of its float, but the volume has raised by 4007044. The volume of shorted shares rised to 38.012 million from 34.005 million shares over the last two weeks. The average intraday trading volume has been 6.745 million shares, which means that days to cover moved to roughly 5.635643.
In the last trading session, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) dropped by -$0.19 over the week and lost -$0.1 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $6.29. The stock recorded its established 52-week high on 05/12/20.
Since 11/14/19, the stock has traded to a low of $1.38 at 187.68%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 2.6. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, BioCryst Pharmaceuticals, Inc.’s two-week RSI is 42.06. This suggests that the stock is neutral at the moment and that BCRX shares’ price movement remains stable. The stochastic readings are equally revealing at 13.98% meaning the BCRX share price is currently in overbought territory.
The technical chart shows that the BCRX stock will likely settle at between $4.04 and $4.11 per share. However, if the stock dips below $3.88, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $3.79.
Currently, the stock is trading in the red of MACD, with a reading of -0.2. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Maxim Group assigned BCRX a rating of Neutral in their intiating review released on June 17. Barclays analysts upgraded their recommendation of the stock from Equal Weight to Overweight while keeping its target price at $7 in a flash note released to investors on May 05. BofA/Merrill seeing the improvements upgraded the stock from Neutral to Buy on November 15, placing it at $5 to $4.
The average rating for the BCRX equity is 2.11 and is currently gathering a bullish momentum. Of 9 analysts tracking BioCryst Pharmaceuticals, Inc. polled by Reuters, 3 rated BCRX as a hold. The remaining 6 analysts were split evenly. However, the split wasn’t equal as a majority (6) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Zacks Consensus Estimate forecasts that the current-quarter revenues for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will decrease by about -99.88%, which will see them reach $3.56 million. The company’s full-year revenues are, however, expected to diminish by about -37.24%, down from $48.84 million to $30.65 million. BCRX’s expected adjusted earnings should drop almost -26.47% to end up at -$0.25 per share, while for the fiscal year, analysts project the company’s earnings to drop by about -1.06% to record -$0.93/share.